Silo Pharma Inc
NASDAQ:SILO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Silo Pharma Inc
Income from Continuing Operations
Silo Pharma Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Silo Pharma Inc
NASDAQ:SILO
|
Income from Continuing Operations
-$4.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-26%
|
|
|
PVH Corp
NYSE:PVH
|
Income from Continuing Operations
$25.3m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-27%
|
|
|
Levi Strauss & Co
NYSE:LEVI
|
Income from Continuing Operations
$538.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
9%
|
|
|
Tapestry Inc
NYSE:TPR
|
Income from Continuing Operations
$522.3m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Ralph Lauren Corp
NYSE:RL
|
Income from Continuing Operations
$918.5m
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
|
VF Corp
NYSE:VFC
|
Income from Continuing Operations
$223.9m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
Silo Pharma Inc
Glance View
Silo Pharma, Inc. engages in the development of streetwear apparel brands. The company is headquartered in Englewood Cliffs, New Jersey. The company went IPO on 2012-01-05. The firm is focused on merging traditional therapeutics with psychedelic research for people suffering from indications, including depression, post-traumatic stress disorder (PTSD), Parkinson's disease and other neurological disorders. The firm is focused on the use of psilocybin as a therapeutic. Psilocybin is considered a serotonergic hallucinogen and is an ingredient in some species of mushrooms.
See Also
What is Silo Pharma Inc's Income from Continuing Operations?
Income from Continuing Operations
-4.2m
USD
Based on the financial report for Dec 31, 2025, Silo Pharma Inc's Income from Continuing Operations amounts to -4.2m USD.
What is Silo Pharma Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-26%
Over the last year, the Income from Continuing Operations growth was 4%. The average annual Income from Continuing Operations growth rates for Silo Pharma Inc have been -3% over the past three years , -10% over the past five years , and -26% over the past ten years .
